Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin

Si Xuan Koo; Sock Hoai Chan; Joanne Ngeow

doi:10.1136/bcr-2015-212978

Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin

Si Xuan Koo, Sock Hoai Chan, Joanne Ngeow^*

^*Corresponding author for this work

National Cancer Centre

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.

Original language	English
Article number	212978
Journal	BMJ Case Reports
Volume	2016
DOIs	https://doi.org/10.1136/bcr-2015-212978
Publication status	Published - Jan 4 2016
Externally published	Yes

Bibliographical note

Publisher Copyright:
Copyright 2015 BMJ Publishing Group. All rights reserved.

ASJC Scopus Subject Areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bcr-2015-212978

Cite this

@article{01c1e95662624a0bacfeda724a8b8b84,

title = "Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin",

abstract = "A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.",

author = "Koo, {Si Xuan} and Chan, {Sock Hoai} and Joanne Ngeow",

year = "2016",

month = jan,

day = "4",

doi = "10.1136/bcr-2015-212978",

language = "English",

volume = "2016",

journal = "BMJ Case Reports",

issn = "1757-790X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin

AU - Koo, Si Xuan

AU - Chan, Sock Hoai

AU - Ngeow, Joanne

PY - 2016/1/4

Y1 - 2016/1/4

N2 - A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.

AB - A Chinese man who had undergone a curative high anterior resection for sigmoid cancer was administrated XELOX (capecitabine and oxaliplatin) as postoperative adjuvant chemotherapy. He subsequently developed sinusoidal obstruction syndrome (SOS) that resolved on discontinuation of XELOX treatment. Genetic evaluation determined that he had the GSTT1-null and GSTM1-null genotype, known to be an independent risk factor for developing oxaliplatin-induced SOS.

UR - http://www.scopus.com/inward/record.url?scp=84956683737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956683737&partnerID=8YFLogxK

U2 - 10.1136/bcr-2015-212978

DO - 10.1136/bcr-2015-212978

M3 - Article

C2 - 26729828

AN - SCOPUS:84956683737

SN - 1757-790X

VL - 2016

JO - BMJ Case Reports

JF - BMJ Case Reports

M1 - 212978

ER -

Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin

Abstract

Bibliographical note

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this